NDAINJECTIONINJECTABLE1 Generic Approved
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Regonol (pyridostigmine bromide) is an injectable acetylcholinesterase inhibitor administered to reverse neuromuscular blockade during anesthesia. It works by inhibiting the breakdown of acetylcholine, restoring neuromuscular transmission after surgical paralysis. The drug is used primarily in perioperative settings to restore muscle function at the end of anesthesia.
$0.042BPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D utilization, suggesting a stable but niche specialist market with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Regonol offers limited career momentum given its mature LOE status, off-patent landscape, and zero linked job openings. Career value lies primarily in specialized hospital and anesthesia relationships rather than broad commercial growth or brand-building opportunities.
Medical Science LiaisonClinical Field Specialist
Worked on REGONOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.